ÎçÒ¹¾ç³¡ Receives Extended MHRA Pharmaceutical Manufacturer’s Licence and GMP Certificate

PRESS RELEASE

Deeside, UK, 10 June 2026: ÎçÒ¹¾ç³¡, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces the renewal and extension of its Manufacturer’s Licence and GMP Certificate by the UK Government’s Medicines & Healthcare products Regulatory Agency (MHRA). 

The company has held an MHRA Manufacturer’s Licence for the past five years. Following a further inspection, the scope of its Licence and GMP Certification has been extended, and the Company now has full regulatory authorisation to also perform in-house analytical testing of its challenge meal products, strengthening internal oversight across manufacturing and quality activities.

In preparation for the approval, ÎçÒ¹¾ç³¡ has undertaken a significant expansion of its analytical capabilities. This has included the establishment of new laboratory spaces, the purchase and qualification of analytical equipment, the development and extension of its Pharmaceutical Quality System to support in-house analysis, and the training of its team to carry out analytical testing to the required regulatory standards. Together, these activities ensure that the organisation is equipped to deliver analytical services within its own facilities in line with MHRA requirements.

Paul Abrahams, CEO of ÎçÒ¹¾ç³¡ said: “I am grateful to the team for all the hard work and commitment that went into preparing for our inspection and for ensuring that it was a success. We believe we are the only oral food challenge (OFC) supplier manufacturing to full pharmaceutical GMP standard and operating worldwide. This extended certification by the MHRA further strengthens our position as a specialist partner in the development and manufacture of OFC materials for clinical trials, contributing to the advancement of food allergy research globally.â€�

Jan Phillips, Head of Quality at ÎçÒ¹¾ç³¡ added: “This is a significant milestone for ÎçÒ¹¾ç³¡ and reflects the continued investment, commitment and hard work across our business to maintain the highest regulatory and compliance standards. By bringing analytical testing in-house, we can offer our customers further operational efficiency, strengthened quality assurance and increased responsiveness in supporting their clinical development programmes.â€�

About ÎçÒ¹¾ç³¡

ÎçÒ¹¾ç³¡ is a UK-based pharmaceutical manufacturer specialising in the development and production of oral food challenge materials for use in clinical trials. With a strong focus on quality, safety and regulatory compliance, the company works with global pharmaceutical and biotechnology partners to support the progress of food allergy research.

Media Contacts

At the company – Lara Marks
Marketing & Communications Officer
E: lara.marks@reactahealthcare.com T: +44 (0)3332 423 042

Charles Consultants

Sue Charles – E: Sue@charles-consultants.com T: +44 (0)7968 726585

Chris Gardner – E: Chris@CGComms.onmicrosoft.com T: +44 (0)7956 0310

Officially accredited as a Great Place to Work Certified organisation

Press Release

Deeside – 2 June 2026 – ÎçÒ¹¾ç³¡, a UK-based pharmaceutical manufacturer specialising in the development and production of oral food challenge materials for clinical trials, has been officially accredited as a Great Place to Work Certified organisation.

This certification is a significant achievement, based on validated and anonymous feedback from ÎçÒ¹¾ç³¡ employees and collected through Great Place To Work. As the global authority on workplace culture, Great Place To Work uses its rigorous, data-driven For Allâ„¢ methodology to evaluate employee experience. This accreditation has confirmed that 90% of employees consistently report a positive experience at ÎçÒ¹¾ç³¡.

“The consistent positive feedback from our employees about their experiences with colleagues, leaders, and roles is immensely meaningful. We will use this fantastic achievement as a benchmark to further enhance our employee experience moving forward. Thank you to our employees whose honest and candid input into the survey has enabled us to earn this prestigious recognition.�

– Paul Abrahams, ÎçÒ¹¾ç³¡ CEO

“Achieving a 90% positive employee experience score is particularly meaningful when measured against Great Place to Work’s established benchmarks, and it reflects the strength of our culture relative to high-performing organisations. These results show that our employees’ day-to-day experience at ÎçÒ¹¾ç³¡ is not only positive, but stands out in a way that reinforces our position as an employer of choice.â€�

– Sophie Griffthis Head of People

Survey results further reinforce this positive culture, with 90% of employees describing ÎçÒ¹¾ç³¡ as a great place to work, 87% expressing pride in the work they do, and 92% highlighting a strong sense of camaraderie across the organisation.

Reflecting on the organisation’s collaborative culture, one employee shared:

“At ÎçÒ¹¾ç³¡, I genuinely feel that everyone is on the same team. There is a shared commitment to success across departments, and people consistently support one another rather than working in silos. It creates a culture where you feel valued, trusted and motivated to do your best work.â€�

Highlighting the sense of purpose underpinning the work, another colleague commented:

“Every day I feel that I am making a meaningful difference in food allergy for millions of people. There is a real sense of purpose in the work we do, combined with a supportive and collaborative environment that makes it a pleasure to come to work.�

Benedict Gautrey, Managing Director of Great Place To Work UK, expressed his congratulations to ÎçÒ¹¾ç³¡ for attaining their Certificationâ„¢:

“We know that prioritising the employee experience leads to building trust among employees, fostering a remarkable workplace culture, and ultimately achieving exceptional business outcomes. Congratulations!â€�

ÎçÒ¹¾ç³¡ Engagements in Beijing and Hong Kong Supporting Education and Global Health

Press Release

14th May 2026

Throughout May, ÎçÒ¹¾ç³¡ demonstrated its continued commitment to education, scientific exchange and international collaboration across Asia through participation in two strategic events.

At the EAACI Allergy School in Beijing, ÎçÒ¹¾ç³¡ sponsored a dedicated symposium focused on advancing understanding of oral food challenges, supporting the development of clinical practice as allergy centres in China continue to expand their capabilities in this area.

“Supporting education around oral food challenges is especially important as more allergy centres in China begin to introduce these procedures into clinical practice. We were pleased to sponsor a symposium at the EAACI Allergy School workshop in Beijing and contribute to an environment of learning, collaboration, and scientific advancement in food allergy management.�

– Martin Wickham, Chief Innovation Officer

ÎçÒ¹¾ç³¡ also participated in the Summit on Global Health in Hong Kong as part of the UK Department for Business and Trade mission, engaging with stakeholders across the regional healthcare ecosystem and strengthening international connections.

“We were delighted to be part of the Department for Business and Trade mission to Hong Kong, supporting stronger connections between UK innovation and the healthcare ecosystem in Asia. The visit provided an excellent opportunity to introduce ÎçÒ¹¾ç³¡â€™s expertise to new partners and stakeholders, while highlighting the strength of UK entrepreneurship, scientific innovation, and collaboration on the international stage.â€�

– Martin Wickham, Chief Innovation Officer

ÎçÒ¹¾ç³¡ extends its thanks to the organisers, partners and delegates involved in both events.

ÎçÒ¹¾ç³¡ Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board

Press Release

ÎçÒ¹¾ç³¡, today announces the appointment of Professor Gary Wing-Kin Wong, internationally recognised paediatric allergy and respiratory disease expert and President-Elect of the World Allergy Organisation (WAO), to its Advisory Board, as the company accelerates new product development and expands its Asia-Pacific (APAC) footprint.

Prof. Wong is Professor of Paediatrics at The Chinese University of Hong Kong and brings global clinical and research experience from Canada and Germany. He helped establish Hong Kong’s participation in the International Study of Asthma and Allergies in Childhood (ISAAC), one of the world’s largest collaborative studies in allergy and asthma, spanning more than 100 countries and nearly two million children. He received the KIA Research Excellence in Allergic Diseases Award (2018) and has played a leading role in shaping international standards and best practice in allergy care.

An export-driven business, ÎçÒ¹¾ç³¡ has increased its workforce by 60% over the past year to support its existing and new customers in Europe and the United States. The company is now building on this momentum by deepening support for international partners and pursuing new collaborations across the APAC region.

ÎçÒ¹¾ç³¡ has pioneered the development and manufacture of pharmaceutical-grade OFC products designed to improve the safety, accuracy and consistency of food allergy diagnostics and to support global clinical research programmes. With APAC, particularly Greater China, continuing to grow as a centre of excellence for clinical development, ÎçÒ¹¾ç³¡ is increasing its engagement with regional investigators, trial specialists and partners to help advance robust, standardised allergy diagnostics.

Prof. Wong said: “ÎçÒ¹¾ç³¡ stands out in food allergy diagnosis for its innovation and its commitment to setting new standards in the field. I look forward to working with the Company as it continues to explore ways to empower the development of therapies and diagnostics that impact the lives of people living with food allergies.â€�

Prof. Wong’s appointment follows that of Richard Nagle as Chair and aligns with the company’s strategic focus on new products and new markets to drive future growth. 

Paul Abrahams, CEO of ÎçÒ¹¾ç³¡, said: “Food allergy therapeutics and diagnostics are evolving rapidly. As an innovative, science-led business, we are actively pursuing new opportunities and new markets to better meet customer needs. We benefit enormously from the clinical and scientific guidance of our advisors, and we are delighted to welcome Prof. Wong to ÎçÒ¹¾ç³¡â€™s Advisory Board.

“I also wish to take this opportunity to thank Professors Barbara Ballmer-Weber and Montserrat Fernandez Rivas, both of whom have recently stepped down, for their contribution to the Adboard since its inception.�

ÎçÒ¹¾ç³¡â€™s ’s Innovation team, led by Chief Innovation Officer, Martin Wickham, will visit China in the coming months to engage with allergy clinical trial specialists. Activities include hosting a symposium at EAACI Allergy School in Beijing (7-9 May), attending the Asia Summit on Global Health in Hong Kong (11-14 May), and participating in the EAACI regional oral food challenge workshop in Hong Kong (5-6 June) with Prof. Agnes Leung.

ÎçÒ¹¾ç³¡ Engages with the Global Allergy Community at AAAAI, Philadelphia

Industry News

ÎçÒ¹¾ç³¡ had a strong presence at this year’s AAAAI Annual Meeting in Philadelphia, where colleagues represented the business and showcased our pharmaceutical grade oral food challenge materials to the global allergy community.

Across the week, the team met with clinicians, researchers and industry partners who share our commitment to improving the accuracy and consistency of food allergy diagnosis. Discussions focused on the importance of high quality, standardised challenge materials and the role they play in strengthening study reproducibility and dose standardisation.

The meeting also provided valuable opportunities to demonstrate ÎçÒ¹¾ç³¡â€™s approach, connect with existing collaborators and introduce our work to new partners. The team closed the week by hosting a reception for invited partners, which offered further opportunities to build relationships and explore future collaboration.

ÎçÒ¹¾ç³¡ Appoints Richard Nagle as Chair of Board of Directors

Press Release

Richard brings more than 30 years’ experience in the pharmaceutical, biotechnology and medical technology sectors including in immunology. He has founded and led multiple companies, raised tens of millions of dollars of funding, achieved a number of successful exits and delivered operational transformations as companies grow. 

Among his senior leadership positions, Richard was a Strategic Advisor and CEO at Immune Regulation (now Revolo Biotherapeutics and formerly Peptinnovate) in which roles he oversaw significant strategic advancements, clinical and product development programs and corporate development during periods of significant growth. In addition to his role as Chair of ÎçÒ¹¾ç³¡, he is a part-time Executive Director at SASPiPhi, a company developing precision antimicrobials.

Richard’s appointment strengthens ÎçÒ¹¾ç³¡â€™s senior leadership as the Company continues its rapid growth driven by its leading position as the only oral food challenge product manufactured under full pharmaceutical GMP, and its innovation pipeline which will fuel future strategic expansion.

Professor Ashley Woodcock, a co-founder of ÎçÒ¹¾ç³¡ and Chair since inception remains with the Company in a Non-Executive Director role.

Dr. Paul Abrahams, ÎçÒ¹¾ç³¡ CEO, said: “We are thrilled to have Richard join us at such a pivotal time in the Company’s growth trajectory. His specific knowledge in the immunology space and broad experience in finance, corporate strategy and product development adds huge value and strengthens our strategic leadership. The senior team and I are looking forward to working with Richard to refine and deliver on an ambitious strategy for 2026 and beyond.

“We are hugely grateful to Ashley for his entrepreneurial leadership, guidance and support of ÎçÒ¹¾ç³¡ to date and look forward to his ongoing contribution to the business as a Non-Executive Director.â€�

Richard Nagle, ÎçÒ¹¾ç³¡ Chair added: “This is an extremely exciting time for ÎçÒ¹¾ç³¡, and I am delighted to be joining this dynamic business. ÎçÒ¹¾ç³¡ has been at the forefront of food allergy diagnostics R&D and counts many of the leading companies in the allergy therapeutic development space as its partners. Our aim now is to continue to expand our presence both in the UK and internationally, delivering solutions that improve the safety, accuracy and efficiency of food allergy testing.

“ÎçÒ¹¾ç³¡ has built a world class team to execute on its future development goals, and I look forward to working with Paul and the management team in helping them to realise maximum value from its pioneering products and deep innovation pipeline.â€�

Development of multi-allergen site and first production of egg and milk
challenge meals

Press Release

20 th May 2025 marks another key milestone for ÎçÒ¹¾ç³¡, as the first
production run of milk and egg challenge meals commence on site for the first time.
These first orders will be shipped overseas for a phase III and a phase II clinical trial
investigating novel food allergy treatments.

The importance of considering multiple food allergies in both diagnosis and
treatment has become increasingly evident. Many individuals suffering from food
allergies often experience reactions to more than one allergen, making it crucial for
healthcare providers to adopt a holistic approach. . Clinicians can focus care on the
needs of the individual which improves patient outcomes and enhances the quality of
life for those affected by food allergies.

The addition of egg and milk challenge meals to the existing peanut products at
ÎçÒ¹¾ç³¡ highlights the significance of addressing multiple allergens in
clinical trials. These products are designed to meet the needs of food allergy
research and clinical communities, ensuring safety, quality, and efficacy across
various allergens. The standardised development of these new allergen products
allows for easy expansion of the product portfolio with further allergens.

Full development and manufacture of the new products has been undertaken at the
Medicines & Healthcare products Regulatory Agency (MHRA) licensed site in
Deeside, UK. The products were designed using the Quality by Design approach
which is a systematic and strategic approach employed in pharmaceuticals. This
ensures the consistent delivery of high-quality products with a pre-determined
objective to ensure that the product is fit for intended use. A standardised approach
across multiple allergens has been implemented to ensure the safety, quality, and
efficacy of the challenge meals.

The challenge meals comply with client requirements for allergen identification,
standardisation, and cGMP manufacturing.

Products come complete with dossier suitable for submission of IND Module 3.
Successful submissions of these dossiers have been made to various health
agencies including FDA and EMA on numerous occasions since 2017.

These challenge meals are suitable for supply to phase I, II and III clinical trials for
use in double-blind placebo-controlled oral food challenges. With the addition of 2
more allergens ÎçÒ¹¾ç³¡ is ideally placed to supply various challenge meals to clinical
trials seeking an ‘antigen agnostic’ indication for their respective therapy. The multi-
allergen site is now set up to seamlessly develop further allergen challenge meals as
demand increases across the USA ‘Top 9’ allergens: milk, eggs, peanuts, fish, crustacean shellfish, tree nuts, wheat, soybeans, and sesame.

The company is eagerly exploring new opportunities to leverage these innovative
products to revolutionise the food allergy research and clinical community. ÎçÒ¹¾ç³¡ is
exploring innovative new solutions, using advanced technology and research to
improve food allergy diagnosis and management.

About ÎçÒ¹¾ç³¡
ÎçÒ¹¾ç³¡, established in 2013, operates from a pharmaceutical
manufacturing facility in the UK. The MHRA licensed facility is licenced to manufacture oral challenge meals, for use in clinical trials, as non-investigational medicinal products (NIMPs)/auxiliary medicinal products (AxMPs). The ÎçÒ¹¾ç³¡ challenge meals are currently used to diagnose and monitor food allergy in numerous global therapeutic trials. Patents for the challenge meals have been granted in a number of countries.